We're sunsetting PodQuest on 2025-07-28. Thank you for your support!
Export Podcast Subscriptions
cover of episode #303 - A breakthrough in Alzheimer’s disease: the promising potential of klotho for brain health, cognitive decline, and as a therapeutic tool for Alzheimer's disease | Dena Dubal, M.D., Ph.D.

#303 - A breakthrough in Alzheimer’s disease: the promising potential of klotho for brain health, cognitive decline, and as a therapeutic tool for Alzheimer's disease | Dena Dubal, M.D., Ph.D.

2024/5/27
logo of podcast The Peter Attia Drive

The Peter Attia Drive

AI Deep Dive AI Chapters Transcript
People
D
Dena Dubal
P
Peter Attia
Topics
Dena Dubal: 本期节目讨论了Klotho蛋白及其对脑健康和认知功能的影响。Klotho蛋白是一种由Klotho基因编码的蛋白质,主要在肾脏中产生,并以可溶性形式分泌到血液中。研究表明,Klotho蛋白水平随着年龄的增长而下降,慢性压力也会降低Klotho水平,而运动则会增加Klotho水平。在小鼠模型中,Klotho蛋白的过表达可以增强认知能力,改善阿尔茨海默病和帕金森病的症状。在非人灵长类动物模型中,外周注射Klotho蛋白可以增强认知能力,这种作用可以持续数周。研究人员发现,Klotho蛋白通过激活血小板并释放血小板因子4(PF4)来间接影响大脑,PF4可以穿过血脑屏障并作用于神经元上的GluN2B受体,从而增强突触可塑性和认知功能。此外,研究人员还发现,Klotho基因的一个变异体KLVS与更高的Klotho蛋白水平和更好的认知功能相关,并且可以减轻APOE4基因对阿尔茨海默病风险的增加作用。 Peter Attia: 本期节目主要关注Klotho蛋白对脑健康和阿尔茨海默病的影响。主持人Peter Attia与神经学家和神经科学家Dena Dubal博士讨论了Klotho蛋白的生物学特性、调控机制及其对认知功能和脑健康的潜在益处。他们探讨了Klotho蛋白在小鼠、灵长类动物和人类模型中的研究结果,以及Klotho蛋白与血小板因子4(PF4)和GluN2B受体之间的相互作用。此外,他们还讨论了Klotho基因变异体KLVS对Klotho蛋白水平和阿尔茨海默病风险的影响,以及Klotho蛋白作为阿尔茨海默病治疗药物的潜力。

Deep Dive

Shownotes Transcript

View the Show Notes Page for This Episode)

Become a Member to Receive Exclusive Content)

Sign Up to Receive Peter’s Weekly Newsletter)

Dena Dubal is a physician-scientist and professor of neurology at UCSF whose work focuses on mechanisms of longevity and brain resilience. In this episode, Dena delves into the intricacies of the longevity factor klotho: its formation and distribution in the body, the factors such as stress and exercise that impact its levels, and its profound impact on cognitive function and overall brain health. Dena shares insights from exciting research in animal models showing the potential of klotho in treating neurodegenerative diseases as well as its broader implications for organ health and disease prevention. She concludes with an optimistic outlook for future research in humans and the potential of klotho for the prevention and treatment of Alzheimer’s disease.

Disclosure: Peter is an investor in Jocasta Neuroscience, a company working to develop klotho as a therapy for people with Alzheimer’s disease.

We discuss:

  • Dena’s fascination with aging and how she came to study klotho [3:30];
  • Biological properties of klotho: production, regulation, decline with age, and factors influencing its levels [11:45];
  • Potential benefits of klotho on brain health [22:00];
  • The relationship between soluble klotho protein, platelet factors, and cognitive enhancement [33:45];
  • The role of platelet factor 4 (PF4) and it’s interaction with GluN2B in mediating cognitive enhancement [46:45];
  • Benefits of klotho observed in a mouse model of Parkinson’s disease [55:45];
  • Benefits of klotho observed in a mouse model of Alzheimer’s disease [1:03:00];
  • Promising results of klotho in primate models, and the importance of finding an appropriate therapeutic dose before moving to human trials [1:08:00];
  • Speculating why a single klotho injection has such long-lasting effects [1:25:30];
  • Potential cognitive benefits of klotho in humans, the impact of the KL-VS genetic variant on klotho levels, and the need for human trials to confirm these effects [1:27:45];
  • The interaction between the KL-VS genetic variant and APOE4 and how it impacts risk of Alzheimer’s disease [1:34:45];
  • The significance of klotho levels: studies linking lower levels to increased mortality and the broader implications for organ health and disease prevention [1:47:15];
  • Measuring klotho levels and determining an individual’s KL-VS status [1:52:15];
  • The promising potential of klotho for Alzheimer’s disease treatment, and the importance of philanthropy for funding research [1:58:00]; and
  • More.

Connect With Peter on Twitter), Instagram), Facebook) and YouTube)